Research programme: neurological disorders therapies - Allergan/SyntaxinAlternative Names: SXN 113
Latest Information Update: 17 Jul 2015
At a glance
- Originator Health Protection Agency
- Developer Syntaxin
- Class Analgesics; Botulinum toxins; Recombinant proteins
- Mechanism of Action SNARE protein antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders